Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Cancer Res. 2018 Sep 5;78(23):6594–6606. doi: 10.1158/0008-5472.CAN-18-1583

Fig. 5. Effects of TIMP3 and MMP3 on CT26 tumor growth.

Fig. 5.

(A) Expression of TIMP3 protein in CT26-VTIMP3 and CT26-VGFP determined by immunoblotting. (B) Final tumor volumes of VTIMP3 and VGFP derivatives injected s.c. (n=10). (C) Weights of orthotopic VTIMP3 and VGFP tumors (n=10). (D) Kaplan-Meier survival plots of mice following splenic injection of VTIMP3 and VGFP cells. (E). Kaplan-Meier survival plots of mice following splenic injection with VTIMP3 cells and treatment with vehicle or Senexin B (diet + oral). (F) Immunoblotting analysis of MMP3 protein knockdown with different shRNAs. (G) Final tumor volumes of control and MMP3 knockdown derivatives injected s.c. (n=10. (H) Kaplan-Meier survival plots of mice following splenic injection of control and MMP3 knockdown cells. (E). Kaplan-Meier survival plots of mice following splenic injection with MMP3 knockdown cells treated with vehicle or Senexin B (diet + oral).